Next Generation Vaccines for Multi-Resistant Bacteria

Mission

Discover and develop safe and effective vaccines to overcome infectious challenges threatening global public health

Vision

A world free of suffering from infectious diseases

Proxi Biotech's BACTOVAC platform technology offers superior vaccines to overcome the challenge of resistant bacteria

Antimicrobial resistance (AMR) is one of the world's most pressing medical problems. More than 700,000 people die each year from infections resistant to antibiotics. By 2050, such infections are expected to kill 10,000,000 people.

Proxi Biotech, an early stage spin-off from the Serum Institute of Denmark, has developed the BACTOVAC platform technology for detoxification of bacterial toxins. BACTOVAC overcomes main barriers of traditional vaccine developing technologies that allows new, highly needed vaccine to enter market and fight multi-resistant bacteria

News

June 2020 - The TRANSVAC2 program

TRANSVAC2 has agreed to support a range of immunological studies on our C. difficile vaccine candidate

June 2020 - Eurostars program

Thanks to the Eureka-Eurostars program for their belief and support in our development plan for a vaccine against C. difficile infections. We are extremely proud of being ranked among the top 5% of the submitted applications and look forward to starting a new consortium with LiteVax BV and Cellvax SAS

May 2020 - EIT Health Headstart

Proud to announce being among the winners of EIT Health Headstart 2020 and very grateful for their support in our quest for developing next-generation vaccines against multi-resistant bacteria

September 2019 - Proxi Biotech is awarded an InnoBooster grant

We are pleased by the support from Innovation Fund Denmark to help build a strong patent backed up by additional preclinical studies

September 2019 - The Nordic Life Science Days

Proxi Biotech is nominated at Nordic Life Science Days

August 2019 - Pharma Danmark article

Proxi Biotech is featured in Pharma Danmark with a cover story on innovative technology for developing vaccines against antimicrobial-resistant bacteria (August 2019)

May 2019 - Proxi Biotech wins the Business Acceleration Award

The BII Business Acceleration Academy ended with a pitch competition at demo day

March 2019 - Business Acceleration Academy at BioInnovation Institute

Proxi Biotech is selected to attend the three-month Business Acceleration Academy program at BioInnovation Institute in Copenhagen

Contact information

Proxi Biotech ApS

Nørre Allé 41

2200 Copenhagen

Denmark

Tel: +45 2255 2202

Email: rj@proxibiotech.com